{
    "clinical_study": {
        "@rank": "19984", 
        "arm_group": {
            "arm_group_label": "PEK Fusion Protein Vaccine", 
            "arm_group_type": "Experimental", 
            "description": "PEK Fusion Protein Vaccine Injection 0.1mg, 0.3mg and 1.2mg One injection at one week intervals"
        }, 
        "brief_summary": {
            "textblock": "Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose\n      Regimen of Escalating Doses of PEK Fusion Protein Vaccine in Women with LSIL or HSIL.\n\n      PEK fusion protein vaccine (PEK + GPI-0100) is safe and well tolerated in patients with\n      low-grade squamous intraepithelial lesions (LSIL) or high grade squamous intraepithelial\n      lesions (HSIL) of the cervix and induces a measurable immune response."
        }, 
        "brief_title": "Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cervical Intraepithelial Neoplasia", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Cervical Intraepithelial Neoplasia", 
                "Carcinoma in Situ"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female age 18 to 45 years\n\n          -  Written informed consent in accordance with institutional guidelines\n\n          -  Negative pregnancy test\n\n          -  LSIL or HSIL on Papanicolaou (PAP) smear within the prior 6-8 weeks\n\n          -  Normal electrocardiogram (ECG), laboratory values (chemistry, complete blood count)\n             and urinalysis, as judged by Grade 0-1 as per National Cancer Institute Common\n             Toxicity Criteria (NCI-CTC) performed up to 30 days prior to administration of study\n             treatment.\n\n          -  Body mass index (BMI) \u226432 kg/m2\n\n          -  Women of child-bearing potential (WOCBP) agree to use two forms of medically\n             effective contraception (e.g. hormonal contraception, intrauterine device, barrier\n             method, spermicide, etc\u2026) during the study and for at least 12 weeks following the\n             completion of treatment.  Patients agree to inform the investigator immediately if\n             they become pregnant during the study or within 12 weeks following completion of\n             treatment and to provide information about the pregnancy, delivery and health of the\n             infant until the age of one month.\n\n          -  Able and willing to comply with all study procedures\n\n        Exclusion Criteria:\n\n          -  Active infection with herpes simplex virus (HSV)\n\n          -  Positive serologic test for human immunodeficiency virus (HIV), Hepatitis C virus\n             (HCV), or Hepatitis B surface antigen (HBsa)\n\n          -  Pregnant or breast-feeding\n\n          -  History of any prior cervical surgical treatment\n\n          -  History of any active autoimmune disease or current medical condition requiring the\n             use of systemic or topical corticosteroids (excluding steroid containing eye drops or\n             inhaled steroids) or other immunosuppressive agents within 4 weeks prior to\n             enrollment\n\n          -  History of cancer (excluding basal cell carcinoma of the skin)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2\n\n          -  Administration of any blood product within 3 months of enrollment\n\n          -  Administration of any vaccine within 6 weeks of enrollment\n\n          -  Active infection requiring antimicrobial treatment\n\n          -  Participation in any study with an investigational compound or device within 30 days\n             prior to signing informed consent\n\n          -  Any hematologic disorder involving platelets or clotting abnormalities or any\n             condition requiring treatment with transfusions, anticoagulants or platelet\n             inhibitors\n\n          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,\n             would interfere with adherence to study protocol\n\n          -  Any condition which, in the opinion of the investigator, would limit the evaluation\n             of the patient."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01880411", 
            "org_study_id": "HBPEKVPI001"
        }, 
        "intervention": {
            "arm_group_label": "PEK Fusion Protein Vaccine", 
            "description": "PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant", 
            "intervention_name": "PEK Fusion Protein Vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "PEK fusion protein Healthbanks", 
        "lastchanged_date": "June 14, 2013", 
        "number_of_arms": "1", 
        "official_title": "Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine (PEK + GPI-0100) in Patients With LSIL or HSIL", 
        "overall_official": {
            "affiliation": "University of Pennsylvania", 
            "last_name": "Christina S Chu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with adverse events.", 
            "safety_issue": "Yes", 
            "time_frame": "6 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01880411"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "HealthBanks Biotech Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "HealthBanks Biotech Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}